Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer

Gastric Cancer

Volumn 19, Issue 1, 2016, Pages 255-263

  Kanda, Mitsuro ^a   Kobayashi, Daisuke ^a   Tanaka, Chie ^a   Iwata, Naoki ^a   Yamada, Suguru ^a   Fujii, Tsutomu ^a   Nakayama, Goro ^a   Sugimoto, Hiroyuki ^a   Koike, Masahiko ^a   Nomoto, Shuji ^a   Murotani, Kenta ^b   Fujiwara, Michitaka ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gastric cancer; Prognosis; Splenectomy; Transfusion

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ALLOGENEIC BLOOD TRANSFUSION; ARTICLE; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; GASTRECTOMY; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SPLENECTOMY; STOMACH CANCER; SURVIVAL RATE; VERY ELDERLY; ADVERSE EFFECTS; ALLOTRANSPLANTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OPERATIVE BLOOD LOSS; PATHOLOGY; PROCEDURES; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; FEMALE; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; SPLENECTOMY; STOMACH NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84951569441     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0456-x     Document Type: Article

References (34)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27–39.
3. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v50–4.
4. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.
5. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477–90.
6. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.
7. Ojima T, Iwahashi M, Nakamori M, Nakamura M, Naka T, Katsuda M, et al. Association of allogeneic blood transfusions and long-term survival of patients with gastric cancer after curative gastrectomy. J Gastrointest Surg. 2009;13:1821–30.
8. Zhou HY, Yi W, Wang J, Zhang J, Wang WJ, Hu ZQ. Association of perioperative allogeneic blood transfusions and prognosis of patients with gastric cancer after curative gastrectomy. Am J Surg. 2014;208(1):80–7.
9. Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Transfusion alert for patients with curable cancer. World J Surg. 2007;31:2315–22.
10. Hyung WJ, Noh SH, Shin DW, Huh J, Huh BJ, Choi SH, et al. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol. 2002;9:5–12.
11. Sanchez-Bueno F, Garcia-Marcilla JA, Perez-Abad JM, Vicente R, Aranda F, Lujan JA, et al. Does perioperative blood transfusion influence long-term prognosis of gastric cancer? Dig Dis Sci. 1997;42:2072–6.
12. Moriguchi S, Maehara Y, Akazawa K, Sugimachi K, Nose Y. Lack of relationship between perioperative blood transfusion and survival time after curative resection for gastric cancer. Cancer (Phila). 1990;66:2331–5.
13. Sobin LH, Gospodarowicz MK. International Union Against Cancer. TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009.
14. Kanda M, Shimizu D, Nomoto S, Hibino S, Oya H, Takami H, et al. Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer. J Surg Oncol. 2014;110:136–44.
15. Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, et al. Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer 2014. doi:10.1007/s10120-014-0372-0
16. Japanese gastric cancer treatment guidelines. ver. 3. Gastric Cancer. 2010;2011(14):113–23.
17. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.
18. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.
19. Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, et al. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. 2014;44(9):1692–701.
20. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105:198–208.
21. Pacelli F, Rosa F, Marrelli D, Pedrazzani C, Bossola M, Zoccali M, et al. Do perioperative blood transfusions influence prognosis of gastric cancer patients? Analysis of 927 patients and interactions with splenectomy. Ann Surg Oncol. 2011;18:1615–23.
22. van Hilten JA, van de Watering LM, van Bockel JH, van de Velde CJ, Kievit J, Brand R, et al. Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery. BMJ. 2004;328:1281.
23. Sy MS, Miller SD, Kowach HB, Claman HN. A splenic requirement for the generation of suppressor T cells. J Immunol. 1977;119:2095–9.
24. Blumberg N, Heal JM. Transfusion-induced immunomodulation and its possible role in cancer recurrence and perioperative bacterial infection. Yale J Biol Med. 1990;63:429–33.
25. Sun CF, Hsieh YY, Ngan KW, Wang WT. Search for immunomodulatory effects of blood transfusion in gastric cancer patients: flow cytometry of Th1/Th2 cells in peripheral blood. Ann Clin Lab Sci. 2001;31:171–8.
26. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4 + CD25 + regulatory T cells. Nat Med. 2005;11:1238–43.
27. Baumgartner JM, Silliman CC, Moore EE, Banerjee A, McCarter MD. Stored red blood cell transfusion induces regulatory T cells. J Am Coll Surg. 2009;208:110–9.
28. Nielsen HJ, Werther K, Mynster T, Brunner N. Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion. 1999;39:1078–83.
29. Patel HB, Nasir FA, Nash GF, Scully MF, Kakkar AK. Enhanced angiogenesis following allogeneic blood transfusion. Clin Lab Haematol. 2004;26:129–35.
30. Maeta M, Shimizu N, Oka A, Kondo A, Yamashiro H, Tsujitani S, et al. Perioperative allogeneic blood transfusion exacerbates surgical stress-induced postoperative immunosuppression and has a negative effect on prognosis in patients with gastric cancer. J Surg Oncol. 1994;55:149–53.
31. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery (St. Louis). 2002;131:401–7.
32. Shelby J, Wakely E, Corry RJ. Suppressor cell induction in donor-specific transfused mouse heart recipients. Surgery (St. Louis). 1984;96:296–301.
33. Chen G, Zhang FJ, Gong M, Yan M. Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients. J Zhejiang Univ Sci B. 2007;8:560–5.
34. Remy B, Deby-Dupont G, Lamy M. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. Br Med Bull. 1999;55:277–98.